With quarterly results and M & An activity drivingIn August, the US stock biotechnology sector quietly opened a new round of rising market.$SPDR S & P Biotech ETF (XBI.US) $It is up nearly 12% so far this month.
So is this rally in the biotechnology industry a flash in the pan or a sustained improvement?
Market analysis said that this round of riseThis is partly because most biotech giants reported strong quarterly results in July and early August.
Bryon Lake, global head of ETF Solutions at JPMorgan Asset Management, said sectors such as biotechnology now look attractive after growth stocks were hit by rising interest rates in the first half of the year.
In addition, it is worth noting thatNews of recent acquisitions in the biotechnology industry has spread frequently.This prospect could bring wealth to these biotech companies.
China Merchants (International) said in the previous research newspaper thatMore mergers and acquisitions are expected in the second half of 2002Because the world's top 20 multinational pharmaceutical companies had more than $224 billion in cash at the end of 21 years, while biotech companies are currently valued at historically low levels.
The agency believes thatAs a result, shares of biotech companies may start to rebound as a result of premium acquisitions.(the average premium for a $500m acquisition based on Evaluate Pharma,2015-2020 is about 41-103 per cent.)
In the first half of this year, there have been some large premium acquisitions (more than $3 billion).Including Pfizer Inc's acquisition of Biohaven for $11.6 billion (an 80 per cent premium to Biohaven's previous closing price) and BMS's acquisition of Turning Point for $4.1 billion (a premium of about 122 per cent). In mid-June, Merck was considering buying Seagen, which focuses on ADC (with a market capitalization of about $30 billion).
It is worth noting thatIn the second half of the year, pharmaceutical companies have sold out some large mergers and acquisitions one after another.
August 8th$Pfizer Inc (PFE.US) $Announced plans to acquire drug makers of sickle cell disease (SCD)Global Blood Therapy (GBT.US) $The deal estimated its market capitalization at $5.4 billion.
On August 8th, it was reported$Savis Health (CVS.US) $Interested in acquiring health care platform$Signify Health (SGFY.US) $.
August fourth$Amgen Inc (AMGN.US) $AnnounceWill be acquired at $52 per share in cash.Autoimmune Diseases Pharmaceutical Biotechnology Company$ChemoCentryx (CCXI.US) $This means that the enterprise value of ChemoCentryx is about $3.7 billion.
August fourth$Gilead Sciences Inc (GILD.US) $It said it would buy privately held biotech company MiroBio for $405 million.
July,$Vertex (VERX.US) $It has announced that it will buy privately held biotech company ViaCyte for $320 million to increase its influence in diabetes.
Niu friends.
Strong performance superimposed hot mergers and acquisitions
Is there any hope of a recovery in the US stock biotechnology industry?
Welcome to leave your wonderful insights in the comments area.
Edit / somer